LP173593-7
Adalimumab Ab
Active
Description
Antibodies to adalimumab were shown to develop in 67% of patients within the first 28 weeks of treatment. Only thirteen percent of patients with adalimumab antibodies experienced relief from symptoms compared to 48% of patients without antibodies to adalimumab. Only 4% of patients with antibodies went into remission compared to 34% of patients who achieved remission without anti-adalimumab antibodies. Antibodies to adalimumab reduced the likelihood that patients would have relief from disease symptoms or go into remission. PMID: 21486979 Source: Regenstrief LOINC
Basic Part Properties
- Part Name
- Adalimumab Ab
- Part Display Name
- Adalimumab Ab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2013-07-28
- Construct for LOINC Short Name
- Adalimumab Ab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP173593-7
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| pl-PL | Polish (Poland) | Adalimumab Ab Synonyms: Przeciwciała do adalimumabu |
LOINC Copyright
Copyright © 2025 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://